Develops and manufactures specialty pharmaceutical products and therapies. Markets branded pharmaceutical products for autoimmune and rare diseases. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 10% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Our checks did not surface a specific strength to highlight here.
A loss of $489.5M against $1.4B in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.34. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.